Sweden-based Diamyd Medical has announced that the Phase 2 study of NP2 Enkephalin failed to meet the primary objective of reducing pain in subjects with severe intractable cancer pain.

An initial data analysis from the 28 day, double-blind, main study period shows that from day three to day 14, following a single dose of the study drug, the group that received NP2 Enkephalin reported on average no better improvement in pain score than the placebo-treated group.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Diamyd Medical president and CEO, Peter Zerhouni, said that although the company had hoped for a better outcome regarding pain relief in the study, the treatment appeared safe, which is an important finding for the whole NTDDS platform.

"We will continue our analysis of this study, including subgroups and the data from the open-label extension period, to determine how to adapt the development plan for our NTDDS portfolio of drug candidates addressing diseases and symptoms within the nervous system which today cannot be adequately treated," Zerhouni added.

"The treatment was well tolerated, confirming the safety of the company’s NTDDS technology."

The randomised, double-blind study was conducted to evaluate the effect of intradermal injections of NP2 Enkephalin on pain reported by subjects suffering from severe intractable pain due to cancer, as well as to confirm the safety of the treatment.

See Also:

According to the company, data continues to be collected from an open-label extension period of the study, in which subjects received up to two additional doses of NP2 Enkephalin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, all subjects will receive conventional pain therapy throughout the study, including opiate drugs.

The treatment was well tolerated, confirming the safety of the company’s NTDDS technology.

President of Diamyd, the US subsidiary of Diamyd Medical, Darren Wolfe, said: "That the technology appears safe in this trial will expand our development options and other indications may prove better targets for this therapeutic approach, be it with NP2 Enkephalin or other drug candidates from our NTDDS platform."